Key Insights

Highlights

Success Rate

92% trial completion (above average)

Published Results

210 trials with published results (24%)

Research Maturity

516 completed trials (58% of total)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

4.9%

43 terminated out of 885 trials

Success Rate

92.3%

+5.8% vs benchmark

Late-Stage Pipeline

26%

227 trials in Phase 3/4

Results Transparency

41%

210 of 516 completed with results

Key Signals

210 with results92% success43 terminated

Data Visualizations

Phase Distribution

686Total
Not Applicable (314)
Early P 1 (4)
P 1 (58)
P 2 (83)
P 3 (130)
P 4 (97)

Trial Status

Completed516
Recruiting105
Unknown94
Not Yet Recruiting45
Terminated43
Active Not Recruiting30

Trial Success Rate

92.3%

Benchmark: 86.5%

Based on 516 completed trials

Clinical Trials (885)

Showing 20 of 20 trials
NCT07645924Phase 3RecruitingPrimary

A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

NCT06616194Phase 3Active Not RecruitingPrimary

A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine

NCT06972056Phase 4RecruitingPrimary

Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study

NCT05125302Phase 3RecruitingPrimary

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

NCT05156398Phase 3RecruitingPrimary

Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

NCT07425041Not ApplicableCompletedPrimary

Effectiveness of Manual Lymphatic Drainage in the Physiotherapeutic Treatment of Migraine

NCT03539393UnknownPrimary

Fremanezumab Managed Access Program for Pediatric Patients

NCT04530110Phase 3CompletedPrimary

A Trial to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents

NCT07297901Not ApplicableEnrolling By InvitationPrimary

App-based Breathing Program for Migraine Relief

NCT07699549CompletedPrimary

Long-term Atogepant in Real-world Practice

NCT06603558Recruiting

Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine

NCT07720765Recruiting

Optical Coherence Tomography in Neurological Practice: Utility and Applicability Across Neurological Diseases (OCt.IN.N)

NCT07720895Not ApplicableCompletedPrimary

Default Mode Network Connectivity and Nocebo Responses in Migraine: A Functional MRI Study

NCT07646613Phase 2RecruitingPrimary

Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients

NCT07698249Not ApplicableEnrolling By InvitationPrimary

Headache Diary for Migraine Patients

NCT05576467Not ApplicableActive Not RecruitingPrimary

Treatment for Migraine and Mood

NCT06158737Phase 1CompletedPrimary

A Clinical Trial Evaluated the Safety and Tolerability, Pharmacokinetic and Pharmacodynamics Profile, and Immunogenicity of a Single Dose of JS010 Injection in Healthy Subjects

NCT06417775Phase 3Active Not RecruitingPrimary

Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

NCT06695156Not ApplicableCompletedPrimary

Exploring the Effect of the Transcendental Meditation® Technique on Migraine Frequency, Intensity, and Functionality: A Single-Arm Study

NCT03836040Phase 3Active Not RecruitingPrimary

Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine

Scroll to load more

Research Network

Activity Timeline